Sudeep Pharma

Sudeep Pharma Limited IPO Details

Sudeep Pharma Limited, a leading manufacturer of pharmaceutical excipients, mineral-based specialty products, and food-grade additives, is preparing to launch its Initial Public Offering (IPO). Established in Ahmedabad, Sudeep Pharma is known for producing high-quality calcium and mineral derivatives used across industries such as pharmaceuticals, nutraceuticals, food processing, personal care, and animal nutrition.

With over three decades of experience, the company has built a strong domestic and international presence, exporting to multiple countries and supplying major pharma and FMCG companies in India. The upcoming IPO aims to support capacity expansion, strengthen R&D capabilities, and enhance global distribution.

IPO Bidding Information

The IPO will include a fresh issue of shares and may also feature an offer for sale (OFS) by existing investors. Details such as price band, issue size, lot size, and listing dates will be announced closer to the launch.

Proceeds from the IPO are expected to be used for:

• Increasing manufacturing capacity for specialty mineral products

• Investing in advanced R&D for pharma-grade excipients

• Enhancing export capabilities and distribution networks

• Upgrading production technology and automation

• Strengthening working capital requirements

The company plans to list on both NSE and BSE.

Key Highlights

• Sudeep Pharma is a trusted name in mineral-based excipients with a portfolio that includes Calcium Carbonate, Calcium Citrate, Dicalcium Phosphate (DCP), Tricalcium Phosphate (TCP), and Precipitated Minerals.

• The company serves leading pharmaceutical and nutraceutical brands in India and internationally.

• Its products comply with IP, BP, USP, and EP standards, ensuring global-quality benchmarks.

• Strong customer base across sectors such as pharma formulations, OTC products, nutrition supplements, food processing, cosmetics, and veterinary feed.

• Established manufacturing facilities backed by stringent quality controls and advanced laboratories.

IPO Objectives

The goals of the Sudeep Pharma IPO include:

• Expanding manufacturing infrastructure to meet rising global demand.

• Strengthening R&D to diversify into high-margin specialty excipients.

• Enhancing logistics capabilities and export channels.

• Supporting general corporate purposes and improving financial flexibility.

• Providing a partial exit to existing stakeholders, strengthening the company’s market visibility.

Financial Performance

Sudeep Pharma has demonstrated steady revenue growth over the years, driven by demand for high-quality mineral excipients in both domestic and export markets.

For FY2023, the company achieved estimated revenues of over ₹500 crore, supported by:

• Strong volumes in pharma-grade mineral products

• Long-term supply contracts with major formulation companies

• Stable contribution from export markets

• High repeat order rate due to product consistency and reliability

The company maintains healthy operating margins due to efficient production processes and a diversified product mix. With increasing global demand for high-quality pharmaceutical excipients, Sudeep Pharma is positioned for continued growth.

Company Strengths

• Industry leadership in mineral-based pharmaceutical excipients

• Wide and diversified product portfolio

• Strong customer relationships with reputed pharma and FMCG companies

• Compliance with international quality standards

• Robust global export presence

• Experienced management and technical team

Industry Outlook

The global pharmaceutical excipients market is expected to grow at a CAGR of over 6–7%, supported by rising demand for formulations, nutraceuticals, and specialty minerals. India, being a global pharma hub, is driving substantial demand for high-quality excipients.

Sudeep Pharma, with its strong manufacturing base, quality consistency, and global reach, is well-positioned to capitalize on industry growth, making its IPO an attractive opportunity for long-term investors.